, Nous comparons ici l'efficacité et l'innocuité d'un biosimilaire du rituximab, Truxima ®

I. Celltrion, République de Corée) avec le rituximab de référence, MabThera ® , chez des patients atteints de SEP

S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel et al., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N Engl J Med. 14 févr, vol.358, issue.7, pp.676-88, 2008.

P. Alping, T. Frisell, L. Novakova, P. Islam-jakobsson, J. Salzer et al.,

, Rituximab versus fingolimod after natalizumab in multiple sclerosis patients, Ann Neurol. juin, vol.79, issue.6, pp.950-958, 2016.

J. Salzer, R. Svenningsson, P. Alping, L. Novakova, A. Björck et al.,

, Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy, Neurology, vol.15, issue.20, pp.2074-81, 2016.

T. Spelman, T. Frisell, F. Piehl, and J. Hillert, Comparative effectiveness of rituximab relative to IFN-? or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry, Mult Scler, vol.24, issue.8, pp.1087-95, 2018.

P. Durozard, A. Maarouf, C. Boutiere, A. Ruet, B. Brochet et al., Efficacy of rituximab in refractory RRMS, Mult Scler, vol.25, issue.6, p.36, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02066062

C. Zecca, F. Bovis, G. Novi, M. Capobianco, R. Lanzillo et al., Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience, Mult Scler, p.1352458519872889, 2019.

Y. Naegelin, P. Naegelin, S. Von-felten, J. Lorscheider, J. Sonder et al., Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis, JAMA Neurol. 1 mars, vol.76, issue.3, p.81, 2019.

M. J. Stubbs, R. Low, S. Mcguckin, R. Newton, M. Thomas et al.,

, Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura, Br J Haematol. juin, vol.185, issue.5, pp.912-919, 2019.

A. Mullard, Bracing for the biosimilar wave, Nat Rev Drug Discov, p.1

S. Simoens, G. Verbeken, and I. Huys, Biosimilars and market access: a question of comparability and costs?, Target Oncol. déc, vol.7, issue.4, p.31, 2012.

S. Simoens, Biosimilar medicines and cost-effectiveness, Clinicoecon Outcomes Res, vol.3, pp.29-36, 2011.

C. L. Ventola, Biosimilars: part 1: proposed regulatory criteria for FDA approval

, P T. mai, vol.38, issue.5, pp.270-87, 2013.

B. Calo-fernández and J. L. Martínez-hurtado, Biosimilars: Company Strategies

, Capture Value from the Biologics Market. Pharmaceuticals (Basel). 12 déc, vol.5, issue.12, pp.1393-408, 2012.

M. Mccamish and G. Woollett, The state of the art in the development of biosimilars

, Clin Pharmacol Ther. mars, 2012.

N. Dunn, A. Juto, M. Ryner, A. Manouchehrinia, L. Piccoli et al.,

, Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies, Mult Scler. 1 août, vol.24, issue.9, pp.1224-1257, 2018.

, Cette motivation était principalement économique (prix du biosimilaire inférieur à celui du MabThera ® , respect du contrat de bon usage qui incite à la prescription de biosimilaires,?) mais aucune étude n'avait montré la sécurité d'utilisation et l'efficacité de ce biosimilaire dans la

, Nous montrons ici que le Truxima ® semble présenter la même tolérance et efficacité que le MabThera ® dans la SEP, avec l'avantage de présenter un coût inférieur. Pour autant, il devient difficile de justifier de l'utilisation de ce biosimilaire dans la SEP en hors-AMM du fait que l'ocrelizumab possède maintenant cette autorisation

, Il serait intéressant à l'avenir de comparer ces deux anti-CD20 dans la SEP

S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel et al., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N Engl J Med. 14 févr, vol.358, issue.7, pp.676-88, 2008.

R. T. Naismith, L. Piccio, J. A. Lyons, J. Lauber, N. T. Tutlam et al., Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial, Neurology. 8 juin, vol.74, issue.23, pp.1860-1867, 2010.

A. Bar-or, P. Calabresi, D. Arnold, D. Arnlod, C. Markowitz et al.,

, Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial, Ann Neurol. mars, vol.63, issue.3, p.400, 2008.

L. Kappos, D. Li, P. A. Calabresi, P. O'connor, A. Bar-or et al.,

, Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebocontrolled, multicentre trial, Lancet, vol.378, issue.9805, pp.1779-87, 2011.

S. L. Hauser, A. Bar-or, G. Comi, G. Giovannoni, H. Hartung et al., Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.19, issue.3, pp.221-255, 2017.

S. Simoens, Biosimilar medicines and cost-effectiveness, Clinicoecon Outcomes Res, vol.3, pp.29-36, 2011.

S. Simoens, G. Verbeken, and I. Huys, Biosimilars and market access: a question of comparability and costs?, Target Oncol. déc, vol.7, issue.4, p.31, 2012.

C. L. Ventola, Biosimilars: part 1: proposed regulatory criteria for FDA approval

, P T. mai, vol.38, issue.5, pp.270-87, 2013.

B. Calo-fernández and J. L. Martínez-hurtado, Biosimilars: Company Strategies to Capture Value from the, Biologics Market. Pharmaceuticals (Basel). 12 déc, vol.5, issue.12, pp.1393-408, 2012.

M. Mccamish and G. Woollett, The state of the art in the development of biosimilars

, Clin Pharmacol Ther. mars, 2012.

D. S. Reich, C. F. Lucchinetti, and P. A. Calabresi, Multiple Sclerosis, N Engl J Med, vol.11, issue.2, p.80, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01480156

E. D'amico, A. Zanghì, M. Gastaldi, F. Patti, M. Zappia et al., Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives, Autoimmun Rev. juill, vol.18, issue.7, pp.665-72, 2019.

M. Duddy and A. Bar-or, B-cells in multiple sclerosis, Int MS J. nov, vol.13, issue.3, p.90, 2006.

C. Lucchinetti, W. Brück, J. Parisi, B. Scheithauer, M. Rodriguez et al.,

, Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination, Ann Neurol. juin, vol.47, issue.6, pp.707-724, 2000.

C. Alcalá, F. Gascón, F. Pérez-miralles, J. A. Domínguez, S. Gil-perotín et al., Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsingremitting multiple sclerosis is effective and safe, J Neurol. mars, vol.266, issue.3, p.34, 2019.

J. F. Kurtzke, A reassessment of the distribution of multiple sclerosis

, Acta Neurol Scand. févr, vol.51, issue.2, p.36, 1975.

G. Rosati, The prevalence of multiple sclerosis in the world: an update, Neurol Sci. Apr, vol.22, issue.2, pp.117-156, 2001.

S. Simpson, L. Blizzard, P. Otahal, I. Van-der-mei, and B. Taylor, Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis, J Neurol Neurosurg Psychiatry, vol.82, issue.10, pp.1132-1173, 2011.

E. Leray, S. Vukusic, M. Debouverie, M. Clanet, B. Brochet et al.,

, Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study, PLoS ONE, vol.10, issue.7, p.132033, 2015.

L. K. Fisniku, P. A. Brex, D. R. Altmann, K. A. Miszkiel, C. E. Benton et al., Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain. mars, vol.131, pp.808-825, 2008.

F. D. Lublin and S. C. Reingold, Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology. avr, vol.46, issue.4, pp.907-918, 1996.

J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker, Multiple sclerosis, N Engl J Med. 28 sept, vol.343, issue.13, p.52, 2000.

K. Hawker, P. O'connor, M. S. Freedman, P. A. Calabresi, J. Antel et al.,

, Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, vol.66, issue.4, p.71, 2009.

F. D. Lublin, S. C. Reingold, J. A. Cohen, G. R. Cutter, P. S. Sørensen et al., Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology. 15 juill, vol.83, issue.3, pp.278-86, 2014.

K. M. Myhr and S. I. Mellgren, Corticosteroids in the treatment of multiple sclerosis

, Acta Neurol Scand, Suppl, vol.73, issue.189, p.80, 2009.

N. Dargahi, M. Katsara, T. Tselios, M. Androutsou, M. De-courten et al., Multiple Sclerosis: Immunopathology and Treatment Update, Brain Sci, vol.7, issue.2017

B. I. Yamout, N. K. El-ayoubi, N. J. , E. Kouzi, Y. Khoury et al.,

, Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study, Journal of Immunology Research, 2018.

D. Sur,

B. Scotti, G. Disanto, R. Sacco, M. Guigli, C. Zecca et al., Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland, PLOS ONE. 14 mai, vol.13, issue.5, p.197415, 2018.

P. Boross and J. Leusen, Mechanisms of action of CD20 antibodies, Am J Cancer Res, vol.2, issue.6, p.90, 2012.

T. Castillo-trivino, D. Braithwaite, P. Bacchetti, and E. Waubant, Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review, PLoS ONE, vol.8, issue.7, p.66308, 2013.

M. E. Barra, D. Soni, K. H. Vo, T. Chitnis, and J. M. Stankiewicz, Experience with longterm rituximab use in a multiple sclerosis clinic, Mult Scler J Exp Transl Clin. déc, vol.2, p.2055217316672100, 2016.

P. Alping, T. Frisell, L. Novakova, P. Islam-jakobsson, J. Salzer et al., Rituximab versus fingolimod after natalizumab in multiple sclerosis patients, Ann Neurol. juin, vol.79, issue.6, pp.950-958, 2016.

J. Salzer, R. Svenningsson, P. Alping, L. Novakova, A. Björck et al.,

, Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy, Neurology, vol.15, issue.20, pp.2074-81, 2016.

T. Spelman, T. Frisell, F. Piehl, and J. Hillert, Comparative effectiveness of rituximab relative to IFN-? or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry, Mult Scler, vol.24, issue.8, pp.1087-95, 2018.

P. Durozard, A. Maarouf, C. Boutiere, A. Ruet, B. Brochet et al., Efficacy of rituximab in refractory RRMS, Mult Scler, vol.25, issue.6, p.36, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02066062

C. Zecca, F. Bovis, G. Novi, M. Capobianco, R. Lanzillo et al., Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience, Mult Scler, p.1352458519872889, 2019.

Y. Naegelin, P. Naegelin, S. Von-felten, J. Lorscheider, J. Sonder et al., Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis, JAMA Neurol. 1 mars, vol.76, issue.3, p.81, 2019.

M. J. Stubbs, R. Low, S. Mcguckin, R. Newton, M. Thomas et al., Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura, Br J Haematol. juin, vol.185, issue.5, pp.912-919, 2019.

A. Mullard, Bracing for the biosimilar wave, Nat Rev Drug Discov, p.1

C. Andrianjafy and L. Peyrin-biroulet, Biosimilars and Inflammatory Bowel Diseases

J. Velayudhan, Y. Chen, A. Rohrbach, C. Pastula, G. Maher et al., Guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance: quality issues (revision 1) -PDF Free Download, BioDrugs. 15 juill, vol.30, issue.4, pp.339-51, 2016.

D. Sur, Guidelineon-similar-biological-medicinal-products-containing-biotechnology-derived-proteinsas-active-substance-quality-issues-revision-1.html 43. Guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance: non-clinical and clinical issues, p.13

L. Développement-des-biosimilaires-|-sandoz-france,

D. Sur,

N. Dunn, A. Juto, M. Ryner, A. Manouchehrinia, L. Piccoli et al.,

, Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies, Mult Scler, vol.24, issue.9, pp.1224-1257, 2018.

D. He, R. Guo, F. Zhang, C. Zhang, S. Dong et al., Rituximab for relapsingremitting multiple sclerosis, Cochrane Database Syst Rev. 6 déc, issue.12, p.9130, 2013.

P. De-flon, M. Gunnarsson, K. Laurell, L. Söderström, R. Birgander et al., Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab, Neurology. 12 juill, vol.87, issue.2, pp.141-148, 2016.